Effect of tigecycline on multidrug resistant Acinetobacter baumannii adeB gene expression and its clinical significance
10.13699/j.cnki.1001-6821.2015.20.013
- VernacularTitle:替加环素对多重耐药鲍曼不动杆菌 adeB 基因表达水平的影响及临床意义
- Author:
Yu-Feng DING
1
;
Shi-Fen LIU
;
Zhen-Tian CHENG
;
Pan-Fei HOU
Author Information
1. 潍坊市益都中心医院 院长办公室
- Keywords:
tigecycline;
Acinetobacter baumannii;
adeB gene
- From:
The Chinese Journal of Clinical Pharmacology
2015;(20):2024-2026
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of tigecycline on multi-drug resistant Acinetobacter baumannii ( MDR -AB ) adeB gene expre-ssion and its clinical significance.Methods A total of 60 clinical iso-lates of multidrug-resistant Acinetobacter baumannii were selected, from which 15 experimental strains with positive result to ciprofloxacin ( CIP) efflux pump encoded gene were screened.The minimum inhibitory con-centration ( MIC) before and after given tigecycline was determined using agar dilution assay, the gene of the strains with large change of MIC value was sequenced and compared.Results The lowest MIC of tigecy-cline to MDR-AB was 2 mg? mL-1 .The MDR-AB′s MIC of tigecy-cline at concentration of 0 , 0.62 mg? mL-1 and ciprofloxacin at 1.25 , 2.5 mg? mL-1 were significantly different ( P<0.05).After tigecycline treatment, adeB gene segment had 15 bases mutation, 5 amino acids are replaced and 4 mutant amino acid had no substitution.The adeB gene expression levels before and after the treatment of tigecyclin were (2.51 ±0.72) and (0.87 ±0.21), statistically significant (P<0.05). Conclusion Tigecycline inhibits MDR -AB efflux pump adeB gene expression, lowers adeB expression levels. Other agents with its combination for the treatment of MDR-AB might improve the clinical efficacy.
